January 2020 FDA Recall Drug by H J Harkins Company Inc Dba Pharma Pac
D-0793-2020 - CGMP Deviations

This Class II drug recall was voluntarily initiated by H J Harkins Company Inc Dba Pharma Pac on January 6, 2020 for the product Drug. The FDA reported the reason for recall as cgmp deviations. The product was distributed in Distributed to Physicians in the following states: CA, FL, NC, and SC. and the recall is currently terminated.

Recall Number: D-0793-2020

Reason for Recall
CGMP Deviations: Presence of NDMA impurity detected in product.
Initiated
01-06-2020
Reported
01-29-2020
Quantity
7,212 tablets

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
H J Harkins Company Inc dba Pharma Pac
Distributed to Physicians in the following states: CA, FL, NC, and SC.
Ranitidine, 150 mg Tablets, a) 7 count, b) 14 count, c) 20 count, d) 30 count, e) 60 count; Rx, Only, H.J. Harkins Company, Inc. dba Pharma Pac Grover Beach, CA 93433 NDC #s: 52959-0502-07, 52959-0502-14, 52959-0502-20, 52959-0502-30 and 52959-0502-60

Batch or Lot Expiration Information

Lot# s: RAN63KG Exp. 05/20, RAN64KG Exp. 10/20, RAN65KG Exp. 11/20, RAN66KG Exp. 05/21